Cyclopharm Limited
ASX CYC.AX
Cyclopharm Limited Gross Profit Margin for the year ending December 31, 2023: 16.57%
-
Cyclopharm Limited Gross Profit Margin for the year ending December 31, 2022 was 25.58%, a 41.41% change year over year.
-
Cyclopharm Limited Gross Profit Margin for the year ending December 31, 2021 was 18.09%, a 27.67% change year over year.
-
Cyclopharm Limited Gross Profit Margin for the year ending December 31, 2020 was 14.17%, a -59.00% change year over year.
-
Cyclopharm Limited Gross Profit Margin for the year ending December 31, 2019 was 34.56%, a -17.92% change year over year.
| Date | Gross Profit Margin | Operating Income Margin | EBT Margin | Net Income Margin |
|---|
| CEO | Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDM |
| IPO Date | Jan. 17, 2007 |
| Location | Australia |
| Headquarters | 1 The Crescent |
| Employees | 87 |
| Sector | Health Care |
| Industries | |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Past 5 years
USD 0.68
StockViz Staff
January 15, 2025
Any question? Send us an email